Pradeep Manudhane, MD
Psychiatry · Canton, OHNPI 1316991599
Payments from drug & device makers
Across 2,312 payments — averaging $655.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$391K
- Alkermes, Inc.$314K
- Vanda Pharmaceuticals Inc.$153K
- Teva Pharmaceuticals USA, Inc.$151K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136K
- Otsuka America Pharmaceutical, Inc.$132K
- plus $238K from 23 others
What the payments were for
- Consulting fees$108,2317%
- Speaking & faculty fees$1,269,94884%
- Travel & lodging$100,0857%
- Food & beverage$37,5722%
- Education$5740%
- Gifts$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 561 | $391,399 |
| Alkermes, Inc. | 482 | $314,380 |
| Vanda Pharmaceuticals Inc. | 172 | $153,014 |
| Teva Pharmaceuticals USA, Inc. | 257 | $151,145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 178 | $136,236 |
| Otsuka America Pharmaceutical, Inc. | 204 | $132,346 |
| E.r. Squibb & Sons, L.L.C. | 112 | $86,937 |
| Axsome Therapeutics, Inc. | 83 | $73,617 |
| Sunovion Pharmaceuticals Inc. | 50 | $34,680 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $19,579 |
| Idorsia Pharmaceuticals US Inc | 29 | $13,995 |
| Eisai Inc. | 21 | $7,162 |
| Neurocrine Biosciences, Inc. | 32 | $655 |
| Johnson & Johnson | 13 | $215 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $212 |
| Lundbeck LLC | 11 | $185 |
| Avanir Pharmaceuticals, Inc. | 8 | $113 |
| Noven Therapeutics, LLC | 7 | $105 |
| Indivior Inc. | 6 | $85 |
| Neuronetics, Inc. | 7 | $71 |
| Ironshore Pharmaceuticals Inc. | 3 | $60 |
| Almatica Pharma LLC | 4 | $58 |
| Adlon Therapeutics L.p. | 3 | $44 |
| Corium, LLC | 3 | $40 |
| Shire North American Group Inc | 2 | $34 |
| Pernix Therapeutics Holdings, Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Validus Pharmaceuticals LLC | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$686,046
- LYBALVI$549,609
- VRAYLAR$378,504
- ARISTADA INITIO$150,715
- Fanapt$149,986
- CAPLYTA$133,161
- REXULTI$127,992
- Auvelity$72,316
- AUSTEDO$56,937
- COBENFY$52,430
- Austedo XR$48,952
- UZEDY$40,645
- LATUDA$33,852
- TRINTELLIX$19,012
- QUVIVIQ$13,248
- Dayvigo$6,643
- VIIBRYD$200
- ABILIFY MAINTENA$108
- ABILIFY ASIMTUFII$108
How this compares
$1,516,410 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 84 | $275,931 |
| AristadaAripiprazole Lauroxil | 52 | $176,406 |
| AustedoDeutetrabenazine | 17 | $162,328 |
| VraylarCariprazine Hcl | 51 | $72,526 |
| RexultiBrexpiprazole | 46 | $68,164 |
| LybalviOlanzapine/Samidorphan Malate | 37 | $58,839 |
| AuvelityDextromethorphan Hbr/Bupropion | 36 | $41,488 |
| CaplytaLumateperone Tosylate | 23 | $38,941 |
| TrintellixVortioxetine Hydrobromide | 47 | $28,530 |
| Chlorpromazine Hcl | 51 | $18,762 |
| BelsomraSuvorexant | 38 | $16,903 |
| Risperdal ConstaRisperidone Microspheres | 24 | $15,303 |
| Paliperidone ErPaliperidone | 35 | $10,140 |
| Divalproex Sodium ErDivalproex Sodium | 106 | $7,277 |
| Quetiapine Fumarate | 212 | $6,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $215 | $291,233108 claims |
| Alkermes, Inc.Aristada, Lybalvi | $314,380 | $235,24489 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $151,145 | $162,32817 claims |
| AbbVieVraylar | $391,399 | $72,52651 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $132,346 | $68,16446 claims |
| Axsome Therapeutics, Inc.Auvelity | $73,617 | $41,48836 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $136,236 | $38,94123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $19,579 | $28,53047 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $1,280170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Canton
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.